



Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study

Mark M. Awad^{1*}, Yvan Le Bruchec², Brian Lu², Jason Ye³, Julie Ann Miller², Patrick H. Lizotte⁴, Megan E. Cavanaugh⁴, Amanda J. Rode⁴, Calin Dan Dumitru² and Alexander Spira⁵

OPEN ACCESS

Edited and reviewed by:

Karen L. Reckamp,
Cedars-Sinai Medical Center,
United States

*Correspondence:

Mark M. Awad
Mark_Awad@dfci.harvard.edu

Specialty section:

This article was submitted to
Thoracic Oncology,
a section of the journal
Frontiers in Oncology

Received: 04 March 2022

Accepted: 02 May 2022

Published: 07 June 2022

Citation:

Awad MM, Le Bruchec Y, Lu B,
Ye J, Miller JA, Lizotte PH,
Cavanaugh ME, Rode AJ,
Dumitru CD and Spira A (2022)
Corrigendum: Selective Histone
Deacetylase Inhibitor ACY-241
(Citarinostat) Plus Nivolumab in
Advanced Non-Small Cell Lung
Cancer: Results From a Phase Ib Study.
Front. Oncol. 12:889996.
doi: 10.3389/fonc.2022.889996

¹ Lowe Center for Thoracic Oncology and Dana-Farber Cancer Institute, Boston, MA, United States, ² Bristol Myers Squibb, Princeton, NJ, United States, ³ Acetylon Pharmaceuticals, Inc, Boston, MA, United States, ⁴ Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, United States, ⁵ Virginia Cancer Specialists (VCS) Research Institute, Fairfax, VA, United States

Keywords: ACY-241, citarinostat, nivolumab, non-small cell lung cancer, HDAC6

A Corrigendum on

Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study

By Awad MM, Le Bruchec Y, Lu B, Ye J, Miller J, Lizotte PH, Cavanaugh ME, Rode AJ, Dumitru CD and Spira A (2021). *Front. Oncol.* 11:696512. doi: 10.3389/fonc.2021.696512

Angeliki Zarotiadou was not included in the Acknowledgments section in the published article. The corrected Acknowledgments section appears below.

“The authors thank the patients who participated in the study and their families. Additional thanks to Precision for Medicine, formerly ApoCell, for serum cytokine and blood immunophenotyping. Biostatistics assistance was provided by Angeliki Zarotiadou, MSc. Writing assistance was provided by Aaron Runkle, PhD, CMPP, of MediTech Media, Ltd, and funded by Bristol Myers Squibb. The authors presented these results in an abstract and poster at the 2019 ASCO Annual Meeting; May 31-June 4, 2019; Chicago, IL (40)”.

In the original article, the reference for NCCN Guidelines[®] for NSCLC V.1.2021 was incorrectly written in the in-text citation as “[Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for NSCL V.1.2021. © National Comprehensive

Cancer Network, Inc. 2021. All rights reserved. Accessed (December 3, 2020). To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way”.

It should be “[Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC V.1.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed (July 20, 2021). To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way]”.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Awad, Le Bruchec, Lu, Ye, Miller, Lizotte, Cavanaugh, Rode, Dumitru and Spira. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.